We examined the effect of streptozotocin-induced maternal diabetes of 6-day duration and 4-to 24-h intracerebroventricular and systemic hyperinsulinism on fetal brain neuropeptide Y (NPY) synthesis and concentrations. Maternal diabetes (n ϭ 6) leading to fetal hyperglycemia (5-fold increase; P Ͻ 0.05) and normoinsulinemia caused a 40% decline (P Ͻ 0.05) in fetal brain NPY messenger RNA (mRNA) and a 50% decline (P Ͻ 0.05) in NPY radioimmunoassayable levels compared to levels in streptozotocin-treated nondiabetic (n ϭ 7) and vehicle-treated control (n ϭ 8) animals. In contrast, systemic hyperinsulinemia (n ϭ 7) of 5-to 100-fold increase (P Ͻ 0.05) over the respective control (n ϭ 7) with normoglycemia caused an insignificant (20 -30%) decrease in fetal brain NPY mRNA and protein concentrations. However, fetal intracerebroventricular hyperinsulinism (n ϭ 7) with no change in fetal glucose concentrations caused a 50 -60% decline (P Ͻ 0.05) in only the NPY peptide levels, with no change in the corresponding mRNA amounts. We conclude that fetal hyperglycemia of 6-day duration and intracerebroventricular hyperinsulinism of 4 -24 h suppress fetal brain NPY concentrations, the former by a pretranslational and the latter by either a translational/posttranslational mechanism or depletion of intracellular secretory stores. We speculate that fetal hyperglycemia and intracerebroventricular hyperinsulinism additively can inhibit various intrauterine and immediate postnatal NPY-mediated biological functions. (Endocrinology 138: [963][964][965][966][967][968][969] 1997) N EUROPEPTIDE Y (NPY), a 36-amino acid peptide, is synthesized in the arcuate nucleus and released by nerve terminals into the paraventricular nucleus of the hypothalamus (1). In addition, this is the most abundant peptide found in the central nervous system with other sites of synthesis, including the cerebral cortex, hippocampus, brain stem, and sympathetic neurons (2, 3). NPY is a neurotransmitter that mediates various biological functions, including anxiolysis, vasomotor reactivity, sexual function, hormone production, and metabolic control (4 -7). The role in the hypothalamus involves orchestrating the feeding behavior of an animal (1, 8 -10). Excess NPY levels cause hyperphagia, whereas low levels lead to anorexic behavior (11-13). Dysregulation of NPY synthesis and secretion can affect various vital biological functions. The synthesis of NPY is regulated by various physiological, hormonal, and metabolic factors in the adult animal (3, 14 -18). Investigations in the adult rat have demonstrated a dysregulation of NPY synthesis and levels by streptozotocin-induced diabetes, a disease state that is associated with hyperglycemia, hypoinsulinemia, and a catabolic energy state (11, 18) . Subsequent studies have revealed that insulin deficiency rather than excess glucose, which is associated with the adult diabetic state, is responsible for the observed NPY alterations (7, 18, 19) .
tions. However, fetal intracerebroventricular hyperinsulinism (n ϭ 7) with no change in fetal glucose concentrations caused a 50 -60% decline (P Ͻ 0.05) in only the NPY peptide levels, with no change in the corresponding mRNA amounts. We conclude that fetal hyperglycemia of 6-day duration and intracerebroventricular hyperinsulinism of 4 -24 h suppress fetal brain NPY concentrations, the former by a pretranslational and the latter by either a translational/posttranslational mechanism or depletion of intracellular secretory stores. We speculate that fetal hyperglycemia and intracerebroventricular hyperinsulinism additively can inhibit various intrauterine and immediate postnatal NPY-mediated biological functions. (Endocrinology 138: [963] [964] [965] [966] [967] [968] [969] 1997) N EUROPEPTIDE Y (NPY), a 36-amino acid peptide, is synthesized in the arcuate nucleus and released by nerve terminals into the paraventricular nucleus of the hypothalamus (1) . In addition, this is the most abundant peptide found in the central nervous system with other sites of synthesis, including the cerebral cortex, hippocampus, brain stem, and sympathetic neurons (2, 3) . NPY is a neurotransmitter that mediates various biological functions, including anxiolysis, vasomotor reactivity, sexual function, hormone production, and metabolic control (4 -7) . The role in the hypothalamus involves orchestrating the feeding behavior of an animal (1, 8 -10) . Excess NPY levels cause hyperphagia, whereas low levels lead to anorexic behavior (11) (12) (13) . Dysregulation of NPY synthesis and secretion can affect various vital biological functions. The synthesis of NPY is regulated by various physiological, hormonal, and metabolic factors in the adult animal (3, 14 -18) . Investigations in the adult rat have demonstrated a dysregulation of NPY synthesis and levels by streptozotocin-induced diabetes, a disease state that is associated with hyperglycemia, hypoinsulinemia, and a catabolic energy state (11, 18) . Subsequent studies have revealed that insulin deficiency rather than excess glucose, which is associated with the adult diabetic state, is responsible for the observed NPY alterations (7, 18, 19) .
Although ontogenic investigations have localized (2, 16 ) and demonstrated considerably lower levels of NPY in fetal rat brain (21) , there are no studies characterizing the effect of an in utero diabetic environment on fetal whole brain NPY expression. Streptozotocin-induced maternal diabetes causes profound metabolic changes in the rat fetus (22) (23) (24) , some of which have a long lasting postnatal effect on growth, peripheral insulin sensitivity, and acquisition of adult-onset obesity (25) , not unlike those in the human (26 -29) . To determine whether fetal whole brain NPY is amenable to the regulatory influences of in utero exposure to a maternal diabetic environment, we undertook the present study and examined the effect of streptozotocin-induced maternal diabetes on fetal brain NPY messenger RNA (mRNA) and peptide levels. In addition, to determine the isolated effect of hyperinsulinism, we examined the short and long term systemic and intracerebroventricular effects of insulin administration on fetal whole brain NPY synthesis and peptide concentrations.
cine's animal care committee, the NIH Guidelines for the Care and Use of Animals were followed. The pregnant animals were allowed at least 1 day of acclimatization before experimental manipulation.
Maternal diabetic model
On day 12 of gestation, rats received either 65 mg/kg freshly reconstituted streptozotocin (Sigma Co., St. Louis, MO) in 0.5 ml vehicle and maintained on ice or an equal volume of the vehicle as described previously (30) . Maternal urine was checked for ketonuria using Ketostix strips (Ames Co., Indianapolis, IN). Maternal tail vein glucose levels were monitored with a One Touch glucose analyzer (Lifescan, Milpitas, CA), and the animals were divided into three groups based on the treatment and glucose values. The vehicle-injected animals demonstrated blood glucoses of less than 10 mm and were assigned to the control group (CON; n ϭ 8). The streptozotocin-injected animals (n ϭ 13) were further divided into two groups. The animals that did not develop overt diabetes were assigned to the streptozotocin nondiabetic group (STZ-ND; n ϭ 7), and had glucose levels below 10 mm. This group served as an additional intermediate group that helped distinguish between the effects of streptozotocin and those of overt maternal diabetes. The rest of the animals that received streptozotocin had glucose levels greater than 13.5 mm and were assigned to the severely diabetic group (STZ; n ϭ 6) (30). On day 20 of an expected 21-day gestation, pregnant rats were anesthetized with pentobarbital and subjected to hysterotomy, and the fetuses were delivered. This experimental model is schematically represented in Fig. 1a .
Fetal hyperinsulinism models
Pregnant rats (n ϭ 28) underwent laparotomy on either day 20 (short term; n ϭ 12) or day 19 of gestation (long term; n ϭ 16) under isofluorane inhalational anesthesia. Upon exposure of the uteri, using microinjection syringes (705NWG, Hamilton Co., Reno, Nevada) fetuses received regular crystalline (short term) or NPH isophane (long term) insulin injections (Sigma Diagnostics) either intracerebroventricularly (1 mU in 2 l vehicle) via the anterior fontanelle or ip (5 mU in 5 l vehicle) through the uterine wall while still maintaining an intact feto-placental unit within the uterus. The respective controls received an equal volume of vehicle. The abdominal incision was closed, and the animals were allowed to recover in their cages. The fetuses were delivered by reopening the hysterotomy incision under pentobarbital anesthesia either 4 h (short term) or 24 h (long term) after laparotomy (31) . This model and the resultant experimental groups are schematically demonstrated in Fig. 1b .
Anthropometric and metabolic characteristics
Maternal body weights were recorded. Pooled fetal body and brain weights from a single litter were recorded, and the mean fetal body and brain weights were derived based on the number of pups per litter. Maternal (intracardiac) and pooled fetal blood (jugular) samples were collected; the plasma was separated by centrifugation at 4 C, aliquoted, and stored at Ϫ20 C until further analyses. Maternal and fetal plasma glucose levels were measured by the quantitative glucose oxidase method (Sigma Diagnostics), and the insulin levels were assessed by the RIA employing a guinea pig antirat insulin primary antibody, 125 Ilabeled insulin as ligand, and rat insulin standards (Linco Research, St. Louis, MO) (30) .
Tissue preparation
Pooled fetal brains from a single litter were snap-frozen in liquid nitrogen and stored at Ϫ70 C under ribonuclease-free conditions. Polyadenylated enriched RNA fraction was extracted using Fast Track kits (Invitrogen, San Diego, CA). RNA was quantitated spectrophotometrically at the 260 nm wavelength. The purity of the RNA samples was documented as a 260/280 nm wavelength optical density ratio of 1.8 to 2, and the integrity of the samples was confirmed by gel electrophoresis (32) .
Northern blot analysis
Ten micrograms of RNA were separated on a 1.2% agarose-2. was assessed by ethidium bromide staining and visualization of RNA under UV light. The RNA samples were transferred to Nytran filters (Micron Separations, Westboro, MA) by capillary action, and the RNA was cross-linked to the filters by exposure to UV light at 1200 ϫ 100 J for 45 sec (Stratalinker 1800, Stratagene, La Jolla, CA). The Nytran filters were prehybridized for 2 h at 42 C in 0.1% polyvinyl pyrolidone, 0.1% BSA, 0.1% Ficoll, 75 mm sodium chloride, 50 mm sodium phosphate monobasic, 1.25 mm EDTA, 0.2% SDS, and 200 g/ml denatured salmon sperm DNA (32) . Hybridization at 42 C for a period of 48 h was accomplished by the addition of 1 ϫ 10 6 cpm/ml of a random primer 32 P-labeled and denatured 511-bp rat prepro-NPY complementary DNA (cDNA) (33) . The filters were then washed at room temperature in 5 ϫ SSC (1 ϫ SSC ϭ 0.15 m sodium chloride and 0.015 m sodium citrate, pH 7.0) and 0.5% SDS twice for 15 min each time, followed by two washes in 1 ϫ SSC and 1% SDS for 30 min each time at room temperature, after which the filters were exposed to x-ray film at Ϫ70 C for various lengths of time until optimal resolution was achieved. Interlane RNA loading was standardized by stripping the filters with 50 mm Tris (pH 8.0), 2 mm EDTA, 0.5% sodium pyrophosphate, 0.002% polyvinyl pyrolidone, 0.002% BSA, and 0.002% Ficoll, ensuring no signal on autoradiography, and then rehybridizing the filters with a 1.0-kilobase (kb) rat 18S ribosomal RNA (rRNA) cDNA probe (34) . All autoradiographs with exposure times within a given range of linearity were subjected to transmittance densitometry (Biomed Instruments, Fullerton, CA), and the optical densities were used to calculate the ratio between the NPY mRNA and 18S rRNA. The ratio was then expressed as a percentage of the corresponding vehicle control sample(s) per blot.
RIA
Brain tissue (100 mg) was extracted in a 10-fold volume of 0.1 n HCl (wt/vol). The fetal brain acid extracts were assayed for NPY by RIA employing a rabbit antirat NPY antibody generated and previously characterized by one of us (35) . [
125 I]NPY (Amersham, Arlington Heights, IL) and porcine NPY standards (Peninsula Laboratories, Belmont, CA) were employed in a RIA using a goat antirabbit serum (Linco Research, St. Louis, MO), and polyethylene glycol was used for precipitation (Fisher, Fairlawn, NJ) (35) . Specific adult and fetal rat brain samples were employed as controls in all assays. The sensitivity of the assay was 15 pg/ml, and the intraassay variability ranged from 2-3%, whereas the interassay variability was 5-8%. The results were expressed per brain weight.
Data analysis
All results are expressed as the mean Ϯ sem. Differences between the streptozotocin-treated severe diabetic, nondiabetic, and vehicle control groups were determined by one-way ANOVA, and the intergroup differences were validated by the Newman-Keuls test. Additionally, nonparametric testing was also conducted using Kruskal-Wallis with tied ranks followed by Dunn's test to ensure that the conclusions drawn were not due to either small numbers or a heteroscedastic distribution of observations. Using both parametric and nonparametric testing, statistically significant differences between the groups were similar. When only two groups were compared, as in the insulin-treated and respective control groups, the Student's t test was used at a P Ͻ 0.05 level of significance. (n ϭ 7), and CON (n ϭ 8) groups was performed and expressed as a ratio to the optical density of the 18S rRNA, and the ratio in each group was depicted as a percentage of that in the CON group. *, P Ͻ 0.05 compared to the STZ-ND and CON groups. c, The radioimmunoassayable NPY peptide levels expressed as a percentage of the vehicle control value (CON; n ϭ 8) is shown for STZ-D (n ϭ 6) and STZ-ND (n ϭ 7) groups. *, P Ͻ 0.05 compared to STZ-ND and CON groups.
Results

Maternal diabetes study
insulin levels were significantly lower than those in the vehicle control group, no difference between the maternal insulin concentrations of the STZ-ND and CON groups was observed. These insulin changes were associated with maternal glucose levels being 3-fold higher in the STZ-D group, with no change in the STZ-ND group. In the fetus, circulating glucose concentrations were 5-fold higher in the STZ-D group compared to those in the STZ-ND and control groups, whereas fetal insulin concentrations were not different among all three groups. STZ-treated maternal diabetic and nondiabetic groups caused no change in fetal body and brain weights. Further, there were no in utero fetal losses.
These maternal diabetes-induced changes in circulating fetal plasma glucose concentrations led to a 40% decline in the fetal brain NPY mRNA (0.8 kb) levels (Fig. 2, a and b) . This decline in mRNA amounts was associated with a 40% decrease in fetal brain immunoreactive NPY levels (Fig. 2c) . The NPY mRNA and peptide levels in the STZ-ND group were not different from those in the vehicle control group. Table 2 demonstrates the fetal plasma glucose and insulin concentrations. As noted, in the short term study, although no changes in circulating glucose concentrations were observed, a 400-fold increase in plasma insulin concentrations was noted in the ip insulin-treated group. In contrast, the intracerebroventricularly insulin-treated group demonstrated only a 10-fold increase in circulating insulin concentrations. In the long term insulin-treated groups, a 5-fold increase in plasma insulin levels was noted only in the ip treated group; the intracerebroventricularly treated group demonstrated no difference compared to the respective control. No change in circulating glucose levels was observed in the long term insulin-treated groups compared to the respective controls. Comparison of fetal glucose levels between the short and long term studies revealed higher levels in the former secondary to the proximity of blood sampling to the laparotomy procedure. At the doses and timing of insulin administration, despite significant hyperinsulinemia in some treatment groups, there were no in utero fetal losses due to the presence of fetal normoglycemia.
Fetal hyperinsulinism studies
Despite interstudy (short vs. long term) differences in fetal plasma insulin concentrations, there were no differences in trends observed between the effects of short and long term insulin treatment on fetal brain NPY mRNA and peptide levels (Fig. 3) . NPY mRNA levels were not different between the insulin-treated groups and the respective control groups in the short term (4-h) studies. Similarly, in the long term (24-h) systemic hyperinsulinemia group, there was no difference in NPY mRNA levels compared to those in the vehicle control. However, a minimal, statistically insignificant decrease in NPY mRNA levels was noted in the long term (24-h) intracerebrally treated insulin group. In contrast, a 50 -60% decline in the immunoreactive NPY levels was observed in both the short term (4-h) and long term (24-h) intracerebrally treated insulin groups compared to those in the respective vehicle-treated control groups. A relatively smaller insignificant trend toward a decline (20 -30%) in NPY levels was also noted in both the 4-and 24-h ip insulintreated groups compared to those in the respective controls.
Discussion
This study demonstrates the presence of NPY in fetal rat brain before the initiation of certain biological functions mediated by this peptide. Intrauterine dysregulation of fetal brain NPY levels can potentially affect in utero and immediate postnatal functions of this neuropeptide. Of all the actions described, including regulation of sexual behavior, vasomotor reactivity, anxiolysis, hormonal secretion, and metabolic control, the most spectacular action of NPY is its capacity to increase robust food intake in satiated animals (36, 37) . Intracerebroventricular administration of NPY leads to increased food intake (8, 9, 11) and delivery of anti-NPY antibodies causes an aversion to food intake in the adult (13) . For this action, NPY is mainly produced in the arcuate nucleus of the hypothalamus, and the nerve fibers project into various hypothalamic sites that are implicated in the regulation of feeding behavior (38, 39) . Considerable levels of NPY are noted in this location in the fetus in addition to smaller levels of expression in the cerebral cortex, hippocampus, and brain stem (2) . In utero, although cyclical feeding has not been established, there is ingestive behavior manifested as swallowing and intake of amniotic fluid, which is essential for the development and maturation of peristaltic movements and epithelial differentiation of the gastro-intestinal tract (40) . The central factors that initiate and promote this in utero swallowing and ingestive behavior remain unknown. In the postnatal period as early as days 2-7 of age in the rat, NPY is a major factor that potentiates hyperphagic behavior leading to increased body weight (41) . This strong association between central NPY levels and food intake supports the contention that NPY serves as an orexigenic central stimulant (1, 8, 12) .
In addition to this orexigenic effect, NPY administration profoundly inhibits both the gonadotropic and somatotropic axes (42) as well as promotes anxiolytic behavior in adult rats (6) . These effects have not been studied in utero or in the immediate postnatal period. Although all these biological functions have been ascribed to NPY, the factors that regulate the synthesis and release of this peptide are currently being explored. In the adult rat, streptozotocin-induced diabetes associated with hyperglycemia and hypoinsulinemia caused an increase in hypothalamic NPY levels (11) . This increase is similar to that observed in a hypoinsulinemic, hypoglycemic, and energydepleted state of starvation (14, 18) . Further systemic administration of insulin was noted to reverse the changes in adult rat hypothalamic NPY concentrations that were induced by the diabetic state (7, 18, 19) . These adult studies collectively demonstrated a predominant role for circulating insulin rather than glucose in regulating NPY synthesis. Recent studies in which insulin was administered intracerebroventricularly, leading to a suppression of hypothalamic NPY levels in both adult control and diabetic rats lend further support to this contention. This decrease in NPY concentrations led to a decline in food intake and body weight (43) . Similar to the adult, whether insulin rather than glucose is involved in regulating fetal brain NPY synthesis remained unknown until the present investigation.
The fetus of a diabetic rat is generally growth retarded due to insufficient placental blood flow (44) . In the present study care was taken to ensure that maternal diabetes was not prolonged or severe enough to interfere with fetal growth. Based on the model employed, there was no major compromise to fetal body and brain weights. Employing this model, our present studies demonstrate that the maternal diabetic state associated with fetal hyperglycemia in the absence of fetal insulin changes led to a decline in fetal brain NPY mRNA and protein levels. This suggests that hyperglycemia alone, in the absence of insulin perturbations, can suppress fetal brain NPY synthesis. The present in utero results contrast the observations of previous studies conducted in the postnatal rat which demonstrated that the progeny of a streptozotocin-induced diabetic pregnant rat develop insulin resistance and obesity during adult life (25) . This change occurs despite postnatal normalization of circulating glucose and insulin concentrations. Thus, the suppression of fetal brain NPY synthesis and concentrations must have an immediate effect on fetal phagic behavior, perhaps resulting in sluggish ingestion of amniotic fluid, thereby contributing to the development of polyhydramnios of a diabetic pregnancy (45) . In addition to its effect on ingestion, the suppression of fetal brain NPY levels in utero may predispose the progeny to altered sexual behavior and a heightened level of anxiety. All of these functional responses to suppressed fetal NPY levels need future investigations.
Four-to 24-h intracerebral exposure to insulin led to a decline in NPY protein concentrations without a similar decline in corresponding NPY mRNA concentrations. These fetal findings are not similar to those noted in the adult rat (18, 43) . This discrepancy may be related to the fact that in the adult, the studies were of longer duration and were carried out over a period of 7-17 days, whereas in the fetus our studies were limited to a maximum of 24 h due to the inability to chronically deliver insulin in vivo to the intact rat fetus. Thus, it appears that over this limited period insulin either suppresses translation or leads to an acute depletion of the secreted NPY peptide. However, our present relatively short term studies do not rule out an added pretranslational suppressive effect on NPY synthesis, which may manifest in future longer term studies, that could be feasible in a larger animal model.
Intraperitoneal insulin administration, which led to phar- Data from the ICS (n ϭ 3 and 4), ICI (n ϭ 3 and 4), IPS (n ϭ 3 and 4), and IPI (n ϭ 3 and 4) groups of the short term (4-h) and long term (24-h) studies, respectively, are shown. *, P Ͻ 0.05 compared to the respective control group. b, Radioimmunoassayable fetal brain NPY peptide levels expressed as a percentage of the respective control value in the short term (4-h) and long term (24-h) study categories are shown in the ICS (n ϭ 3 and 4), ICI (n ϭ 3 and 4), IPS (n ϭ 3 and 4), and IPI (n ϭ 3 and 4) groups. *, P Ͻ 0.05 compared to the respective control groups.
macological levels of circulating insulin concentrations without a change in circulating glucose levels, did not suppress the fetal brain radioimmunoassayable NPY amounts to the same extent as direct administration of the hormone to the brain. Nevertheless, a trend toward a decline in NPY peptide levels was noted in both the 4-and 24-h studies. This suggests that insulin suppresses fetal brain NPY concentrations by a direct action. Thus, high levels of circulating insulin concentrations can only render this effect by crossing the bloodbrain barrier and acting upon the NPY-producing cells. It appears that circulating fetal insulin does not acutely (within 24 h) cross the blood-brain barrier in sufficient amounts necessary to produce a 50% suppression of fetal brain NPY concentrations. Chronic fetal hyperinsulinemia, as observed in the human fetus of a diabetic mother, could cumulatively lead to sufficient intracerebroventricular insulin levels capable of suppressing NPY concentrations. Recent studies in adult animals have demonstrated systemic hyperinsulinemia to increase adipocytic secretion of circulating leptin (46) , which, in turn, binds to leptin receptors in both the choroid plexus and the hypothalamic paraventricular nucleus, leading to a suppression of neuropeptide mRNA levels (47) . In addition to a direct suppressive action of insulin on hypothalamic neuropeptide synthesis (18, 43) , it is feasible that leptin acts as the intermediary for systemic insulin's suppressive effect on hypothalamic NPY. Thus, it appears that both of these peptides influence adult hypothalamic NPY synthesis. In the present study, the measured fetal brain NPY concentrations reflect NPY present in areas of the brain other than the hypothalamus alone. However, the fact that ip insulin administration in the fetus did not have a similar effect as intracerebroventricular administration suggests that pharmacological levels of fetal hyperinsulinemia as achieved in the present study may either not evoke an increase in circulating leptin levels similar to that in the adult or fail to express an adult type leptin-induced suppression of whole brain NPY synthesis. Future studies are required to examine the direct effect of insulin separate from that of leptin on fetal brain NPY concentrations.
We conclude that in the fetus, before the establishment of cyclical postnatal feeding behavior, sexual function, and development of anxiety, hyperglycemia of 6-day duration in the absence of insulin perturbations leads to a pretranslational suppression of fetal rat brain NPY synthesis and levels. In contrast, acute fetal hyperinsulinemia of significant proportion independent of changes in circulating fetal glucose levels fails to alter fetal brain NPY mRNA and peptide concentrations to the same extent. Intracerebroventricular hyperinsulinism independent of hyperglycemia, however, suppresses fetal brain NPY levels, perhaps secondary to either translational or posttranslational effects or an acute depletion of secreted NPY. Thus, in the fetus, hyperglycemia rather than acute hyperinsulinemia appears to have a dominant suppressive effect on fetal brain NPY concentrations. The combined effect of hyperglycemia and chronic hyperinsulinemia leading to intracerebroventricular hyperinsulinism as in the human fetus of a diabetic pregnancy could additively inhibit fetal brain NPY synthesis leading to lowered NPY levels and depressed function. Based on these observations we speculate that this in utero suppression of NPY may perturb the fetal ingestive pattern of amniotic fluid, contributing to the development of polyhydramnios and/or predispose the fetus to altered immediate postnatal feeding behavior, body weight gain pattern, vasomotor stability, sexual function, and level of anxiety.
